BioHarvest Sciences Inc 8MV0.MU is expected to show a rise in quarterly revenue when it reports results on March 31 for the period ending December 31 2025
The Vancouver British Columbia-based company is expected to report a 25.8% increase in revenue to $9.159 million from $7.28 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for BioHarvest Sciences Inc is for a loss of 10 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for BioHarvest Sciences Inc is $12.00, about 177.8% above its last closing price of $4.32
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.11 | -0.11 | -0.14 | Missed | -21.7 |
Jun. 30 2025 | -0.17 | -0.11 | -0.24 | Missed | -118.2 |
Mar. 31 2025 | -0.13 | -0.12 | -0.13 | Missed | -8.3 |
Dec. 31 2024 | -0.12 | -0.12 | -0.17 | Missed | -37.8 |
| |||||
|
This summary was machine generated March 27 at 21:15 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)